Krystal Biotech’s (NASDAQ:KRYS) quiet period is set to expire on Monday, October 30th. Krystal Biotech had issued 3,960,000 shares in its public offering on September 20th. The total size of the offering was $39,600,000 based on an initial share price of $10.00. During Krystal Biotech’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Separately, Ladenburg Thalmann Financial Services started coverage on shares of Krystal Biotech in a report on Wednesday, October 18th. They issued a “buy” rating and a $23.00 price objective for the company.

COPYRIGHT VIOLATION NOTICE: “Krystal Biotech Inc’s Quiet Period To Expire on October 30th (NASDAQ:KRYS)” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/krystal-biotech-incs-quiet-period-to-expire-on-october-30th-nasdaqkrys.html.

Krystal Biotech (NASDAQ:KRYS) opened at 9.99 on Monday. Krystal Biotech has a one year low of $9.42 and a one year high of $11.98. The company has a 50 day moving average of $10.07 and a 200-day moving average of $10.07. The firm’s market cap is $96.33 million.

In other news, COO Suma Krishnan acquired 100,000 shares of the stock in a transaction on Friday, September 22nd. The stock was bought at an average price of $10.00 per share, with a total value of $1,000,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,935,249 shares of the company’s stock, valued at $19,352,490. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Janney acquired 200,000 shares of the stock in a transaction on Friday, September 22nd. The stock was purchased at an average cost of $10.00 per share, with a total value of $2,000,000.00. The disclosure for this purchase can be found here.

About Krystal Biotech

Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.

Receive News & Ratings for Krystal Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.